archive-org.com » ORG » V » VINCENTCAPRIO.ORG

Total: 371

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Vincent Caprio's Blog Evolving Innovations » Blog Archive » NanoBusiness – Nano News Spring 2011 Edition
    CAPITAL Spring 2011 News Startup Kurion Enlisted for Fukushima Cleanup http www greentechmedia com articles read startup kurion enlisted for fukushima cleanup Cambrios ClearOhm Film Used in Smart Phone http www reuters com article 2011 04 06 idUS114178 06 Apr 2011 BW20110406 Interesting Webinar this week WEBINAR Thursday May 19 2011 1 00pm 5 30pm EST Nano Governance The Current State of Federal State and International Regulation http www2 americanbar org calendar nr1105 nano governance Pages default aspx Great report for our Nanotechnology Community 2010 NIST Center for Nanoscale Science and Technology CNST Report http www nist gov cnst upload cnst 2010 report pdf Attached is a fantastic article that was published in the May 2nd edition of Chemical Engineering News entitled U S Nanotech at a Crossroads by Britt E Erickson NNI Hearing Article CEN PLEASE SAVE THE DATE for our 10th Annual NanoBusiness Conference September 25 27 2011 Seaport World Trade Center Boston MA http www seaportboston com meetings and events overview aspx Hotel Seaport Hotel connected to the World Trade Center http www seaportboston com Regards Vincent Caprio Serving the Nanotechnology Community for Over a Decade Executive Director NanoBusiness Commercialization Association 203 733 1949 vincent nanobca org www nanobca org Leave a Reply Name required Mail will not be published required Website Pages Vincent s Bio Vincent s Friends Become a WIAF Individual Member Become a NanoBCA Individual Member Contact Me Vincent Caprio on You Tube Discussing Water Infrastructure Water 2 0 Conference February 26 2013 30 Rockefeller Center New York NYC 5th Annual Nanotech Commercialization Conference April 9 10 2013 Wake Forest Biotech Place Winston Salem NC NanoBusiness Commercialization Association 11th Annual NanoBusiness Conference September 5 7 2012 Boston MA Water Innovations Alliance Home Key Posts Nanotech Commercialization Conference April 9 10 2013 Wake Forest Biotech

    Original URL path: http://www.vincentcaprio.org/nanobusiness-nano-news-spring-2011-edition (2016-05-02)
    Open archived version from archive

  • Vincent Caprio's Blog Evolving Innovations » Blog Archive » NanoBusiness Interview-Dr. J. Steven Rutt, Partner & Chairman, Nano Team, Foley & Lardner
    large volume Unfortunately fewer patents relate to pharma and biotech which is due to how the USPTO defines the classification One must go outside of 977 to monitor nanobio 977 is just a starting point I have been impressed by the broad balanced diversity of patent applicants populating 977 ranging from the Samsungs to the lone inventors from the universities to the mid sized companies and from the government labs to the VC backed start ups Nanotech patent licensing and litigation are alive and well from our experience Universities and federal laboratories continue to aggressively market their patent licensing and will face increasing pressure in coming years to show the government how the government funding for research is translating into jobs Many companies of course want to avoid litigation but if your product is valuable competitors will arise and IP disputes are almost unavoidable at some point there are so many patents out there Smart well managed companies aggressively manage the risks from the very start searching for and formulating strategy for competitive patents Some companies appear to just want to posture and litigation can t always be avoided New things seem to constantly come up For example we monitor deep shale gas drilling patenting and innovation including Marcellus shale which will have a profound impact Now nanotech patents are starting to appear in this innovation space Graphene Metamaterials Always something new SW You mentioned four areas of focus at F L Litigation Corporate Intellectual Property IP and Regulatory Let s discuss regulatory briefly Generally speaking how does the current regulatory environment for nanotech look from your perspective What are the hot topics for nanotech at the EPA and FDA today for example SR Much has been written about nanotech and EHS of course perhaps too much It seems as if more has been written than actually done Innovation tends to flow faster than and not wait for regulation The current climate for budget cutting and promotion of jobs tends to cool the fervor to regulate One topic that should receive more attention than it does is connecting innovation and regulation It can come in several flavors For example one form is innovation to facilitate nanotech regulation If you want to regulate exposure to nanoparticles how do you measure the exposure Is there a way to study nanomaterial toxicity without killing larger animals and minimizing animal rights concerns Other EHS technologies actively do something remedial As an example the Department of Energy recently filed a patent application 2011 0039291 related to bioremediation of nanomaterials EHS is best as an innovation growth area for the coming decade Inventions can help with or be required for the kinds of regulation we want and make sense The EPA is perhaps the most active agency and we have an active environmental regulation group which works with the EPA e g Foley lawyers Sarah Slack Dick Stoll and Steven Chester The EPA should be issuing TSCA nano related rules in 2011 including reporting obligations for manufacturers Another area of activity is regulation of certain public health claims about nanoscale products e g kill germs While we have an active FDA group e g Foley lawyers David Rosen and Nate Beaver the FDA has been seemingly less active with nanotech in recent years Some drug products and medical devices which incorporate nanoparticulate technology have been approved In FDA s discussion of looking ahead for the next five years the FDA recognizes they need to become more involved and keep abreast of new developments and emerging technologies like nanotech As for OSHA not much new for now in the bigger picture One never knows when a crisis might occur to profoundly change the EHS debate No one predicted too well the BP oil spill or the Japan nuclear crisis In the meantime we have slow evolution of regulatory dialog tempered by the need to allow business to grow in a sluggish economy SW With respect to the corporate services F L provides what types of services are most in demand today SR It crosses the gamut For example new emerging tech companies whether they are called nanotech or not are always forming expanding and preparing to take it to the next level such as the next financing round an IPO or being bought They need to be structured and financed through the changes They need grant money Employment matters come up Stock options Lobbying IP Complex agreement issues come up including supply agreements and technical advisory agreements are but some examples Etc Multi disciplinary teams are essential Finally international issues are key including China In particular our corporate lawyers in such offices as Boston and Silicon Valley are active in these areas e g Foley s Jim Chapman Susan Pravda Julie Lee Linda Ji and Ken Duck SW On your blog http www nanocleantechblog com you ve written about the upcoming Supreme Court decision on Bayh Dole Give us some background on the case and tell us what the implications of a ruling in favor or rejection might be SR Briefly the case is Stanford v Roche Oral argument at the Supreme Court was held February 28 2011 and a decision should issue shortly sorry I should avoid saying who will or should win The fact that the Supreme Court agreed to take the case confirms the importance of IP innovation and government funding in the Court s modern mindset The Court could issue a broad sweeping opinion or more likely issue a narrowly tailored opinion This is an important case because it touches on what can happen when federally funded research at the university is linked to private efforts for commercialization The case interprets the Bayh Dole Act which is the legal regime set up thirty years ago to govern IP rights and licensing for federally funded inventions These days most agree that partnering is important for commercialization and partnering includes individuals visiting other organizations to collaborate and learn However this can generate legal problems Here

    Original URL path: http://www.vincentcaprio.org/nanobusiness-interview-dr-j-steven-rutt-partner-chairman-nano-team-foley-lardner (2016-05-02)
    Open archived version from archive

  • Vincent Caprio's Blog Evolving Innovations » Blog Archive » Review of NNI Hearing held by the House Science, Space & Technology Subcommittee April 14th
    rates Dr Teague noted that by current estimates the 2010 nanotechnology funding for the European Community totaled 2 6B US exceeding the NNI total of 1 9B The witnesses encouraged the Subcommittee to continue supporting basic research while also directly promoting technology transfer for example through expanded use of public private partnerships The speakers from industry noted that NNI investments in their companies have generated handsome returns on investment in the form of private follow on funding job creation and cost saving product or process improvements Representative Mo Brooks R AL Chair of the Subcommittee thanked Dr Teague for his eight years of service as Director of the NNCO Dr Teague s last day as Director was April 15 2011 I have attended four of these types of hearings during the last 10 years This review was very focused with the witnesses explaining how a variety of products developed through the Science of Nanotechnology have impacted America Another take away from the hearing is that 2011 2012 US NNI funding is budgeted for 2 1 Billion and the European Union funding is budgeted for 2 6 Billion I spoke at the German House in NYC http www germany info Vertretung usa en events GKs NEWY 2011 04 13 Nanovation html on Wednesday night April 13th and I saw first hand the progress they are making in Germany The NanoBusiness Commercialization Association would like to thank Dr Teague for his service to the NNI and America We offer Dr Teague and his family Best Wishes on the next chapter in his life Regards Vincent Caprio Serving the Nanotechnology Community for Over a Decade Executive Director NanoBusiness Commercialization Association 203 733 1949 vincent nanobca org www nanobca org Leave a Reply Name required Mail will not be published required Website Pages Vincent

    Original URL path: http://www.vincentcaprio.org/review-of-nni-hearing-held-by-the-house-science-space-technology-subcommittee-april-14th (2016-05-02)
    Open archived version from archive

  • Vincent Caprio's Blog Evolving Innovations » Blog Archive » Summary – 2011 NanoBusiness NYC Conference
    with a description of NTI s relationship with Ben Franklin Technology Partners As one of four independent regional entities in the Ben Franklin model NTI has been a leader in developing multi institutional IP agreements and moving university developed IP into companies They work with many partner companies in Southeastern Pennsylvania and beyond with restrictions in place to keep most of the money in state In the past few years the State has shifted more emphasis to funding clean energy following a very similar model while cutting back somewhat on their nanobio and other life science investments We rejoined our NanoBCA colleagues for lunch which included a keynote presentation from PhARMA CEO John Castellani The nano track continued afterward with Jeff Rosedale of Woodcock Washburn surveying the nanomedicine intellectual property landscape To get a big picture of the situation Jeff compared the U S Patent and Trademark Office s Nanotechnology Cross reference Class Class 977 with the A1 international class for medical patents He came up with 2 900 patents 2 300 of them independent in both classes Three out of four describe compositions of nanomaterials or methods for making them Diagnostic devices imaging devices bandages and stents were also common The largest patenters not surprisingly are big corporations Proctor and Gamble L Oreal and Elan The University of California is fourth Jeff used a few just issued patents to illustrate the true state of the art Last Tuesday s new announcement included the following 7 919 699 Nanotubes as mitochondrial uncouplers http patft uspto gov netacgi nph Parser Sect1 PTO2 Sect2 HITOFF p 1 u 2Fnetahtml 2FPTO 2Fsearch adv htm r 3 f G l 50 d PTXT S1 977 2F CCLS OS CCL 977 RS CCL 977 and 7 919 113 Dispersible concentrate lipospheres for delivery of active agents http patft1 uspto gov netacgi nph Parser Sect1 PTO2 Sect2 HITOFF p 1 u 2Fnetahtml 2FPTO 2Fsearch bool html r 1 f G l 50 co1 AND d PTXT s1 dispersible TI s2 concentrate TI OS TTL dispersible AND TTL concentrate RS TTL dispersible AND TTL concentrate from the University of Kentucky and Hebrew University respectively The UK patent is a variation on an 80 year old idea for altering metabolism with applications from weight loss to healing brain injuries While the basic mechanism is demonstrated it has been very difficult to control As in many other similar applications the inventors believe nanotechnology will give them the ability to fine tune the process safely Jeff continued that major pharma manufacturers do have nano patent portfolios including AstraZeneca s supercritical process for dispersing protein particles Bristol Myers Squibb s conjugated MRI contrast agents Ethicon s fluorescent markers to aid surgeons and Abbott s stent which eludes nanoparticles that are both bioactive and contrast enhancing so standard imaging techniques can see when the medicine has all eluted GE as might be expected has many nano patents throughout the biomedical imaging field But with all this activity only one set of patents has made it into the FDA orange book which lists patents of composition or method that are generally recognized as safe and effective That s Elan s TriCor portfolio which is based on ball milling far from a modern technology Moving on to patenting strategies Jeff suggested that inventors should generally focus more on what and less on how since competitors can often find a different way to make something Claim what they need to take steal from you And claim something that is verifiable i e that you can measure Rosedale reminded us that trademarks trade secrets and agreements can be just as important as patents Small companies in particular should be very sure that employees and consultants have proper agreements assigning rights to the company One good basic strategy for balancing these components is to patent your basic compositions consumables devices and tests while keeping non critical details and improvements as trade secrets When conflicting or overlapping IP claims appear what should a company do A good way to start is by asking a patent attorney for a freedom to operate study Their recommendations may range from licensing to requesting re examination of patents based on new found prior art to seeking a declaratory judgment invalidating a patent to as a last and expensive resort doing battle in court Our good friend Scott Livingston http www livingstonsecurities com about php followed Jeff with an update on the investment outlook Scott had just been in Boston for the annual meeting of the National Venture Capital Association which he said was the hottest in several years He met with leading partners from 20 major VC firms they are all looking to get their money working again in companies and IPOs are regaining favor The political landscape is also promising Scott noted President Obama s emphasis on innovation in the State of the Union address Secretary Geithner s recent travels to high tech companies including NanoMech and plenty of interest in innovation on the other side of the aisle he reminded us that the re emergent Newt Gingrich has a long history as a champion of innovation and friend of the NanoBCA Livingston Securities http www livingstonsecurities com expects to continue to be in upcoming quality IPO deals hoping to following on recent successes like Neophotonics and Gevo But business as usual on Wall Street is a risk The big investment firms are not focused on the needs of high tech companies and are pushing them too hard It is especially bad in healthcare Biotech deals are getting canceled or requiring companies to give up too many shares at too low a price leaving them underfunded and unhealthy He described Tesla s much talked about 2010 offering as a different model Sentiment was strong and highly mixed By offering friends and family deals to owners of their first generation Roadster or people on the waiting list they had 1 3 of their deal done with engaged investors before going to the

    Original URL path: http://www.vincentcaprio.org/summary-2011-nanobusiness-nyc-conference (2016-05-02)
    Open archived version from archive

  • Vincent Caprio's Blog Evolving Innovations » Blog Archive » NanoBusiness Interview – Josh Wolfe, Co-founder & Managing Partner Lux Capital Management
    energy goes up Think of it in Internet terms if I gave you an efficient T 1 line you d be doing video conferencing streaming music and sending large files If I put you on a terribly inefficient 56k baud modem you d pull your hair out The secret paradox is that if you want to reduce energy demand you make things more INEFFICIENT NOT more efficient That s if you believe we should be reducing energy demand which I am in the minority opposition Physics and the laws of thermodynamics tell us that life itself is a fight against entropy disorder and the only way to prevent entropy is to add energy to a system The more energy the more order and the more utility we have The highly ordered photons in a laser are hugely valuable to society from eye surgery to photonics whereas the highly entropic photons of a campfire give off heat and nobody will pay much for that The trick is ordering the photons in a laser requires an enormous amount of energy and a huge amount of waste is chucked over the side We have recently announced an investment in Transphorm Inc that we re hugely excited about Transphorm has developed the world s most energy efficient power conversion technology eliminating up to 90 of all electric conversion losses The ability to convert electricity without loss may be to digital power what Intel was to digital logic SW Are there any nano enabled energy technologies that look attractive to Lux JW The basis of our nuclear waste remediation company Kurion was born in sophisticated chemistry and material science at the nanoscale So too our soon to be announced power conversion digital power company coming out of stealth All of these are based on ever increasing precision control over and ordering of matter at the nanoscale SW I want to go back to your investment process The second way Lux Capital invests is based on people Can you give us a few examples of people driven investments you have made and some insight into the thinking behind them JW Yes the first is thesis driven We try to look where others are not looking seeking out where capital and attention are scarce because that s usually where valuations are low and future returns high It s intellectually gratifying to do these but very risky as we really part from the herd and we have to make sure we do our work and aren t being contrarian for unfounded reasons A second way we make our investments is special situations finding capital market dislocations where we can invest often times as the last dollars in but lowest average price per share being a liquidity provider or helping companies when their other investors may be unable to continue financing them And our third and favorite style is people driven as you say As Lux partner Larry Bock says we bet on two legged mammals Darwin was misquoted It isn t survival of the fittest but survival of the most adaptable So we find the brilliant galvanizing scientist entrepreneurs operators usually some combination of two of those three are embodied in one person They are the ones that can adapt and turn on a dime can passionately recruit can paint a vision on a blank canvas that makes investors want to write checks and employees want to plunge in and take career risk A phenomenal individual is just that a phenom a spinning force that pulls people in The most important thing we can do as a firm is have the good judgment in finding and picking these people and convincing them that Lux is their partner for the next 5 or 10 years Our investors trust us to allocate their capital and we have to trust these entrepreneurs to do the same for us SW We ve seen a lot of activity in nanomedicine over the past decade How does Lux view the potential of nanotech in medicine and health care overall JW It s as big as energy The growing trend from big pharma is continued outsourcing to biotechs academic institutions and embracing external R D And the pace of innovation is remarkable We ve spun out companies like Genocea in rapid vaccine discovery from Harvard and Berkeley From MIT in the case of Cerulean and Visterra focused respectively on nanotech in cancer and pandemic flu And from Johns Hopkins in using nanotech to deliver drugs through mucus with MIT legend Bob Langer and his star protégé Justin Hanes in a new company called Kala which is Hawaiian for passageway SW Returning to the other piece of Lux s trilogy investment process what kinds of special situations have you invested in that you are enthused about JW The most interesting might be Everspin We were founding investors who approached Freescale Semiconductor which was previously Motorola Semi They were struggling with a huge debt load from private equity investors after a buyout And we made them an offer to spin out their entire advanced memory division which developed non volatile memory instant on memory and help free up their cash flow It was a win win for everyone and the company has been growing at triple digit percentages SW Nanotech is crucial to the future of semiconductors and electronics How does Lux Capital go about evaluating technologies and companies in this space JW The key particularly in a cyclical industry like semis is who actually is capturing the value There s also a secular component with the rise of Asia contract manufacturing and fab less models The only intelligent thing we felt we could do was to avoid the capital intensive businesses and invest after all the capital was invested at the trough of the cycle In three of our companies over 100 million was invested by either other investors or a corporate parent and we were able to invest at a valuation that was one tenth

    Original URL path: http://www.vincentcaprio.org/nanobusiness-interview-josh-wolfe-co-founder-managing-partner-lux-capital-management (2016-05-02)
    Open archived version from archive

  • Vincent Caprio's Blog Evolving Innovations » Blog Archive » NanoBusiness Interview – William Moffitt, President & CEO, Nanosphere
    bacteria or viruses may be the underlying cause Second the unit use disposable cartridge format makes it economically feasible to run one patient sample at the place and time the physician requests the test Other technologies rely on batch processing many patient samples at one time in order to lower the cost of any single test This is not conducive to providing critical patient information when and where it is required Third operation of the system is so simple that it can be used in virtually any health care setting After the user inserts a sample the Verigene System performs all functions required to provide a test result The system also incorporates an on board quality control system to ensure accurate results SW Nanosphere is pioneering the use of gold nanoparticles in diagnostics technology Why gold WM We functionalize the surface of gold nanoparticles with oligonucleotides or antibodies to create probes for genetic and protein assays On the nanoscale gold exhibits the perfect properties for creating high selectivity and sensitivity in biological probes two attributes critical for the development of assays that must detect the smallest quantities of biological materials Moreover the catalytic properties of gold enable rapid amplification schemes which in our case is the attachment of silver to the particle in the detection phase of the assay This enlarges the particle and increases its light scattering properties Gold s stability at the nanoscale enables us to create reagents with a long shelf life a property that is important in commercializing products for global distribution SW Who are the primary customers for your nano enabled diagnostics technology and what kind of feedback are you getting from the market WM Our primary customers are hospital based clinical laboratories regional reference laboratories and other professional health care settings Feedback has been very encouraging as our customers are excited about the ability to perform complex genetic and infectious disease tests when and where they are needed and in a format that is very simple to operate The Verigene System is enabling testing in locations that could otherwise not perform such diagnostic tests SW What kinds of efficiencies and cost savings are you able to deliver to the market today and how might that evolve in the foreseeable future WM One of the greatest efficiencies delivered to the market is speed to patient diagnosis Enabling tests to be performed at the point of care and as requested by the physician generates critical diagnostic information when and where it is required The high cost and complexity of genetic tests has been eliminated through nanotechnology Nanotechnology has enabled the development of a molecular diagnostics platform that operates in a very simple format thus eliminating the need for highly specialized labor Moreover the underlying cost of the consumable test cartridge is very inexpensive which allows for pricing that is in line with any number of other routine diagnostic tests tens of dollars as opposed to hundreds or thousands SW We are seeing a tremendous decline in

    Original URL path: http://www.vincentcaprio.org/nanobusiness-interview-william-moffitt-president-ceo-nanosphere (2016-05-02)
    Open archived version from archive

  • Vincent Caprio's Blog Evolving Innovations » Blog Archive » NanoBusiness – The Next Decade
    commercialization in the private sector Steve Waite steve nanobca org our new Director of Strategy and Research will be assisting me with this initiative We believe it will be important for our members to stay on top of what is expected to be an acceleration and mass proliferation of nanotech innovations in the future We hope to create a vibrant and interactive community whereby our members can share information with us and where we can help educate and promote their new products to policymakers researchers analysts the financial community and other interested parties Our vision for the NanoBusiness Commercialization Association is clear and focused The Association seeks to ensure that the United States its companies universities and people are global leaders in the burgeoning nanotechnology field And the Association ventures to ensure the safe secure and beneficial use of nanotechnology and nanoscience for all people Our mission at the NanoBCA in the coming decade is three fold 1 Promote the Commercialization of products designed and developed through the Science of Nanotechnology 2 Advocate continued U S spending through the National Nanotechnology Initiative America must continue the funding of NNI from R D to commercialization 3 Inform membership with regard to EHS regulation from Federal EPA and FDA and State Governments Monitor proposed legislation from Federal and State government We are proud of the accomplishments of the NbA over the past decade having successfully lobbied for the creation of The National Nanotechnology Initiative in January 2000 Backed by our supportive members our efforts have helped produce over 12 billion of funding which has created a community of about 150 000 contributors in the U S along with a flexible R D infrastructure consisting of about 100 large nanotechnology oriented R D centers networks and user facilities and an expanding industrial base of about 3 000 companies producing nanotech enabled products Despite all this fabulous growth in activity we are still only in an early stage of development with nanotechnology There is much work ahead and we know that we cannot do it without the support of our members We are very excited to be returning to NYC for our conference being held at the Marriott Marquis Times Square on April 6 7th The conference begins with an opening reception on the evening of Wednesday April 6th We have an entire day of programming on April 7th details to follow REGISTRATION 400 To register please complete the attached form 2011 NanoBCA NYC Reg Form and fax to 480 275 3662 HOTEL INFORMATION New York Marriott Marquis Times Square 212 398 1900 http www marriott com hotels travel nycmq new york marriott marquis 269 per night Room block code NYBA We appreciate your continued support and look forward to working with and serving our members in what promises to be an exciting decade ahead for nanotechnology and the nanotech community It has been a pleasure representing the collective voice of the nanotechnology community I look forward to serving you in the next exciting

    Original URL path: http://www.vincentcaprio.org/nanobusiness-the-next-decade (2016-05-02)
    Open archived version from archive

  • Vincent Caprio's Blog Evolving Innovations » Blog Archive » NanoBusiness Endorses Introduction to Safe Handling of Nanomaterials – Mar. 28th Anaheim, CA
    Four Register five people for one course one person for five courses or any combination in between and your fifth registration is free Note This discount is only available if you register by fax or mail and mention this discount May not be combined with any other offer Register online for this class in Anaheim CA Course Code NANO http www regonline com Register Checkin aspx EventID 916169 Register with form via mail or fax Course Code NANO http www proed acs org courses registration pdf KEY TOPICS Introduction to nanomaterials Toxicology of nanomaterials research review Environmental impact of nanomaterials research review Assessing and controlling exposure to nanomaterials strengths weaknesses of existing technologies Risk managements approaches key elements control banding Regulations and Standards key regulatory agencies activities and standards on nanomaterials Information management in the nanotech workplace essential resources for further education COURSE INSTRUCTOR S Kristen Kulinowski http chemistry rice edu FacultyDetail aspx RiceID 1200 is a Ph D Chemist and director of International Council on Nanotechnology as well as executive director of NSF Center for Biological and Environmental Nanotechnology Bruce Lippy http mysite verizon net bruce lippy html team html is a certified industrial hygienist a certified safety professional and holds a Ph D in policy from the University of Maryland EVENT LOCATION Hilton Anaheim http www hiltonanaheimhotel com 777 Convention Way Anaheim CA 92802 HOTEL RESERVATIONS Discount room reservations can be made through the ACS Housing Connection https resweb passkey com Resweb do mode welcome ei new eventID 3092081 Direct questions about the course to Phone 202 872 4508 Email shortcourses acs org This is a subject that is vital to our nanotechnology community Please continue to educate yourself on this topic Regards Vincent Caprio Executive Director NanoBusiness Alliance 203 733 1949 vincentcaprio nynanobusiness org www nynanobusiness org

    Original URL path: http://www.vincentcaprio.org/nanobusiness-endorses-introduction-to-safe-handling-of-nanomaterials-mar-28th-anaheim-ca (2016-05-02)
    Open archived version from archive



  •